# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Terns intends to use the net proceeds from the proposed offering, to fund research, clinical trials, development and manufactur...
JMP Securities analyst Silvan Tuerkcan maintains Terns Pharma (NASDAQ:TERN) with a Market Outperform and raises the price ta...
Terns Pharmaceuticals announced promising Phase 1 trial results for TERN-601, showing significant weight loss in obese and over...
PLTR: 8% | Palantir Technologies shares are trading higher amid its addition to the S&P 500 index. TERN: 42% | Terns Pharma...